Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomicsStephan M. Tirier, Karsten Rippe, Marc S. Raab et al.|Nature Communications|2021Cited by 141
Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell TransplantationLukas John, Stefan Schönland, Sandra Sauer et al.|Transplantation and Cellular Therapy|2023Cited by 9
Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myelomaLukas John, Nicola Giesen, Kaya Miah et al.|Frontiers in Oncology|2023Cited by 5
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [18F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 TrialChristos Sachpekidis, Antonia Dimitrakopoulou‐Strauss, Marina Hajiyianni et al.|European Journal of Nuclear Medicine and Molecular Imaging|2025Cited by 4
Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment OutcomeSimon Steiger, Marc S. Raab, Raphael Lutz et al.|Blood|2022Cited by 4